Australia - englanti - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - cefalexin monohydrate, quantity: 525.76 mg (equivalent: cefalexin, qty 500 mg) - capsule, hard - excipient ingredients: magnesium stearate; microcrystalline cellulose; gelatin; purified water; titanium dioxide - treatment of the following infections when caused by susceptible strains of the designated microorganisms. respiratory tract infections. caused by s. pneumoniae and group a beta-haemolytic streptococci (penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. cephalexin is generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cephalexin in the subsequent prevention of rheumatic fever are not available at present). bacterial sinusitis. caused by streptococci, s. pneumoniae and s. aureus (methicillin sensitive only). otitis media. due to s. pneumoniae, staphylococci. skin and skin structure infections. caused by staphylococci and/or streptococci. genitourinary tract infections, including acute prostatitis. caused by e. coli, p. mirabilis, and klebsiella sp. the effectiveness of cephalexin in the treatment of bacterial infections of the brain and spinal column has not been established and cephalexin is not indicated in these conditions. note: appropriate culture and susceptibility tests should be initiated prior to and during therapy to determine susceptibility of the causative organism to cephalexin. renal function studies should be performed when indicated.

Australia - englanti - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - pomalidomide, quantity: 4 mg - capsule, hard - excipient ingredients: microcrystalline cellulose; maltodextrin; sodium stearylfumarate; gelatin; titanium dioxide; iron oxide yellow; iron oxide red; indigo blue; erythrosine; shellac - pomalidomide sandoz, in combination with bortezomib and dexamethasone, is indicated for the treatment of patients with relapsed or refractory multiple myeloma who have received at least one prior treatment regimen including lenalidomide. pomalidomide sandoz, in combination with dexamethasone, is indicated for the treatment of patients with relapsed and refractory multiple myeloma who have received at least two prior threatment regimens, including both lenalidomide and bortezomib, and have demonstrated disease progression on the last therapy.

Australia - englanti - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - pomalidomide, quantity: 3 mg - capsule, hard - excipient ingredients: microcrystalline cellulose; maltodextrin; sodium stearylfumarate; gelatin; titanium dioxide; iron oxide yellow; iron oxide red; indigo blue; shellac - pomalidomide sandoz, in combination with bortezomib and dexamethasone, is indicated for the treatment of patients with relapsed or refractory multiple myeloma who have received at least one prior treatment regimen including lenalidomide. pomalidomide sandoz, in combination with dexamethasone, is indicated for the treatment of patients with relapsed and refractory multiple myeloma who have received at least two prior threatment regimens, including both lenalidomide and bortezomib, and have demonstrated disease progression on the last therapy.

Australia - englanti - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - trandolapril, quantity: 4 mg - capsule, hard - excipient ingredients: dimeticone 350; microcrystalline cellulose; lactose monohydrate; pregelatinised maize starch; silicon dioxide; magnesium stearate; titanium dioxide; iron oxide yellow; iron oxide red; erythrosine; gelatin; iron oxide black - treatment of hypertension. data to support the usage of trandolapril in renovascular hypertension are, at present, not available. trandolapril is also indicated for patients with left ventricular dysfunction post myocardial infarction (ejection fraction less than or equal to 35% or wmi (wall motion index) less than or equal to 1.2).

Australia - englanti - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - trandolapril, quantity: 2 mg - capsule, hard - excipient ingredients: dimeticone 350; microcrystalline cellulose; lactose monohydrate; pregelatinised maize starch; silicon dioxide; magnesium stearate; titanium dioxide; sunset yellow fcf; purified water; erythrosine; gelatin; sodium lauryl sulfate - treatment of hypertension. data to support the usage of trandolapril in renovascular hypertension are, at present, not available. trandolapril is also indicated for patients with left ventricular dysfunction post myocardial infarction (ejection fraction less than or equal to 35% or wmi (wall motion index) less than or equal to 1.2).

Australia - englanti - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - trandolapril, quantity: 1 mg - capsule, hard - excipient ingredients: dimeticone 350; microcrystalline cellulose; lactose monohydrate; pregelatinised maize starch; silicon dioxide; magnesium stearate; titanium dioxide; sunset yellow fcf; purified water; erythrosine; gelatin; sodium lauryl sulfate - treatment of hypertension. data to support the usage of trandolapril in renovascular hypertension are, at present, not available. trandolapril is also indicated for patients with left ventricular dysfunction post myocardial infarction (ejection fraction less than or equal to 35% or wmi (wall motion index) less than or equal to 1.2).

Australia - englanti - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - trandolapril, quantity: 0.5 mg - capsule, hard - excipient ingredients: dimeticone 350; microcrystalline cellulose; lactose monohydrate; pregelatinised maize starch; silicon dioxide; magnesium stearate; titanium dioxide; sunset yellow fcf; quinoline yellow; purified water; erythrosine; gelatin; sodium lauryl sulfate - treatment of hypertension. data to support the usage of trandolapril in renovascular hypertension are, at present, not available. trandolapril is also indicated for patients with left ventricular dysfunction post myocardial infarction (ejection fraction less than or equal to 35% or wmi (wall motion index) less than or equal to 1.2).

Australia - englanti - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - tramadol hydrochloride, quantity: 50 mg - capsule, hard - excipient ingredients: magnesium stearate; titanium dioxide; iron oxide yellow; colloidal anhydrous silica; microcrystalline cellulose; gelatin; sodium starch glycollate; sodium lauryl sulfate - zydol capsules are indicated for the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain.

Australia - englanti - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - mercaptamine (cysteamine) bitartrate, quantity: 441.72 mg (equivalent: mercaptamine (cysteamine), qty 150 mg) - capsule, hard - excipient ingredients: microcrystalline cellulose; pregelatinised maize starch; magnesium stearate; sodium lauryl sulfate; silicon dioxide; croscarmellose sodium; titanium dioxide; gelatin; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; iron oxide black; ethanol; shellac; sulfuric acid - for the management of nephropathic cystinosis in children and adults.

Australia - englanti - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - mercaptamine (cysteamine) bitartrate, quantity: 147.24 mg (equivalent: mercaptamine (cysteamine), qty 50 mg) - capsule, hard - excipient ingredients: microcrystalline cellulose; pregelatinised maize starch; magnesium stearate; sodium lauryl sulfate; silicon dioxide; croscarmellose sodium; titanium dioxide; gelatin; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; iron oxide black; ethanol; shellac; sulfuric acid - for the management of nephropathic cystinosis in children and adults.